Fidanacogene Elaparvovec: First Approval
This article summarizes the milestones in the development of fidanacogene elaparvovec leading to this first approval for moderately severe to severe (factor IX activity ≤ 2%) haemophilia B who are negative for neutralizing antibodies to AAVRh74var.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Gene Therapy | Genetics | Haemophilia | Hemophilia | Pfizer | Study